Nanotechnology Now - Press Release: "ThalesNano Announces the Launch of New Products for its H-Cube for Enantio-Selective and Stereo-Selective Catalytic Hydrogenations"

Home > Press > ThalesNano Announces the Launch of New Products for its H-Cube for Enantio-Selective and Stereo-Selective Catalytic Hydrogenations

Abstract:
ThalesNano Inc., announced today that it has validated and launched new products and applications for its H-Cube(TM) bench-top catalytic hydrogenator. H- Cube was recognized as one of the 100 most technologically significant and innovative new products of 2005 by R&D Magazine The new series of CatCarts(TM), ThalesNano's unique catalyst cartridge system for use in its flow reactors, filled with immobilized catalysts will enable scientists to carry out enantio-selective and stereo-selective catalytic hydrogenations while working with the H-Cube(TM). These products will be launched at the American Chemical Society's 233rd National Meeting & Exposition, March 25-29, 2007, in Chicago, IL USA. (for more information visit: http://www.acs.org )

ThalesNano Announces the Launch of New Products for its H-Cube for Enantio-Selective and Stereo-Selective Catalytic Hydrogenations

BUDAPEST, HUNGARY | Posted on March 27th, 2007

Catalytic hydrogenation is one of the cleanest chemical
transformations; however its safe handling has so far required expensive
and special dedicated facilities. ThalesNano's H-Cube(TM) hydrogenation
bench top reactor can perform these transformations safely in standard
laboratories even at high pressure and temperature. As a result of the
extension of the application area, chemists will be able to perform
otherwise complicated enantio-selective hydrogenation reactions in
H-Cube(TM) routinely.
Laszlo Urge, CEO of International Operations said: "These new products
will widen the application area of the H-Cube(TM) hydrogenation reactor
significantly. Enantio-selective hydrogenation represents an important
transformation in the search for novel biologically active compounds, and
is a bottleneck in many of the pharmaceutical industrial processes. It also
requires a special infrastructure that makes it less appealing for
discovery chemistry.
The importance of enantio-selective hydrogenations is underlined by the
fact that scientists who were pioneering this field were awarded the Nobel
Prize in 2001 for their achievements.
An ever increasing number of chemists throughout the pharmaceutical and
biotech industry are utilizing ThalesNano's revolutionary H-Cube(TM), that
makes catalytic hydrogenation in laboratories significantly more effective
than traditional methods. It also allows easy automation even at high
temperature and pressure. This enables chemists to carry out catalyst
screening and quick process optimization while scanning a wide parameter
range. As a result a large number of discovery protocols are currently
created and they will be transferred to development and scale up for the
production of clinical materials. Due to the relatively easy scale up with
ThalesNano flow reactors, the time required to transfer results from
discovery to development could be shortened. Therefore we foresee great
potential for entering process chemistry downstream from discovery with
this new product family soon. "
Dr. Ferenc Darvas, President and Chairman at ThalesNano commented
"These products have great potential and will make the work of chemists
more effective. We are finding more and more applications that cannot be
solved with traditional methods. It also underlines that ThalesNano is
executing a strategy, where we could provide novel solutions not only for
the discovery and for the development phases of the pharmaceutical
industry, but for the petrochemical, food and cosmetics industry as well.
These integrated solutions could effect both discovery and development and
could help solve some of the bottlenecks in the R&D areas."
For more information please refer to ThalesNano's website at
http://www.thalesnano.com

####

About ThalesNano Inc.
ThalesNano is a technology-intensive company that provides solutions
for leading pharmaceutical and biotechnology companies from all over the
world. It is specialized in developing and providing microscale flow
instruments for chemistry, by exploiting the benefits of combining
microfluidics, mezofluidics or nanotechnology with flow chemistry.
The award winning development, H-Cube(TM), has been recognized as one
of the 100 most technologically significant and innovative new products of
2005 by R&D Magazine is the first in a new wave of continuous-flow
hydrogenation reactors. Utilizing water electrolysis to generate hydrogen,
with a catalyst cartridge system and with a continuous-flow reactor, the
shoe-box sized H-Cube(TM) makes hydrogenation convenient, more efficient
and less hazardous. With this equipment, reactions that are almost
impossible to carry out under normal circumstances can be performed. The
product is already on the market and Thales Nanotechnology expects that its
unique development will revolutionize catalytic hydrogenation in the next
decade. (see further details at: http://thalesnano.com/rdaward100press )